Projects per year
Fingerprint Dive into the research topics where James C.M. Brust is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 2 Similar Profiles
Multidrug-Resistant Tuberculosis
Medicine & Life Sciences
South Africa
Medicine & Life Sciences
HIV
Medicine & Life Sciences
Extensively Drug-Resistant Tuberculosis
Medicine & Life Sciences
Tuberculosis
Medicine & Life Sciences
tuberculosis
Agriculture & Biology
Therapeutics
Medicine & Life Sciences
Linezolid
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2010 2020
Safety, pharmacokinetics, and resistance to bedaquiline in XDR TB and HIV
2/5/15 → 1/31/20
Project: Research project
bedaquiline
Extensively Drug-Resistant Tuberculosis
Pharmacokinetics
HIV
Safety
Integrated, Home-based Treatment for MDR TB and HIV in Rural South Africa
5/1/10 → 4/30/16
Project: Research project
South Africa
HIV
Therapeutics
Research
Research Personnel
Publications 2008 2019
1
Citation
(Scopus)
Linezolid pharmacokinetics in South African patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection
Wasserman, S., Denti, P., Brust, J. C. M., Abdelwahab, M., Hlungulu, S., Wiesner, L., Norman, J., Sirgel, F. A., Warren, R. M., Esmail, A., Dheda, K., Gandhi, N. R., Meintjes, G. & Maartens, G., Mar 1 2019, In : Antimicrobial Agents and Chemotherapy. e02164-18.Research output: Contribution to journal › Article
Linezolid
Multidrug-Resistant Tuberculosis
Coinfection
Pharmacokinetics
HIV
Management of active tuberculosis in adults with HIV
Meintjes, G., Brust, J. C. M., Nuttall, J. & Maartens, G., Jul 1 2019, In : The Lancet HIV. 6, 7, p. e463-e474Research output: Contribution to journal › Review article
Tuberculosis
HIV
Immune Reconstitution Inflammatory Syndrome
Drug Interactions
Pharmaceutical Preparations
RpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis: Retrospective analysis of prevalence, phenotypic, genotypic, and treatment outcomes
Mvelase, N. R., Pillay, M., Sibanda, W., Ngozo, J. N., Brust, J. C. M. & Mlisana, K. P., Apr 1 2019, In : Open Forum Infectious Diseases. 6, 4, ofz065.Research output: Contribution to journal › Article
Open Access
Rifampin
Mycobacterium tuberculosis
Rifabutin
Multidrug-Resistant Tuberculosis
Mutation
2
Citations
(Scopus)
A new era for treatment of drug-resistant tuberculosis
Gandhi, N. R., Brust, J. C. M. & Sarita Shah, N., Oct 1 2018, In : European Respiratory Journal. 52, 4Research output: Contribution to journal › Review article
Open Access
Multidrug-Resistant Tuberculosis
3
Citations
(Scopus)
Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities
Auld, S. C., Shah, N. S., Mathema, B., Brown, T. S., Ismail, N., Omar, S. V., Brust, J. C. M., Nelson, K. N., Allana, S., Campbell, A., Mlisana, K., Moodley, P. & Gandhi, N. R., Oct 1 2018, In : The European respiratory journal. 52, 4Research output: Contribution to journal › Article
Extensively Drug-Resistant Tuberculosis
Single Nucleotide Polymorphism
South Africa
Mycobacterium tuberculosis
Genome